Biocon’s arm receives European Commission approval for Biosimilar Bevacizumab

26 Apr 2021 Evaluate

Biocon’s subsidiary -- Biocon Biologics has received marketing authorization approval from the European Commission (EC) for Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. The company has received approval following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Abevmy 100 & 400 mg, a biosimilar Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, nonsmall-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

360.85 -9.25 (-2.50%)
30-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1757.35
Dr. Reddys Lab 1254.65
Cipla 1223.05
Zydus Lifesciences 871.20
Lupin 2312.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×